RenovoRx, Inc. (RNXT) PE Ratio — Current & Historical Data

Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.

rnxt · pe ratio · data through Jun 9, 2026

Core PE Ratio Metrics

Trailing 12 months · TTM

Insufficient PE history data (fewer than 3 valid fiscal years).

PE Ratio vs Peers

Biotechnology · 6 peers · Annual PE

Company	Market Cap	PE (Annual)	vs Avg	EPS (TTM)
RenovoRx, Inc.You RNXT	$34M	N/A	—	-$0.32
Annovis Bio, Inc. ANVS	$36M	N/A	—	-$1.40
BioAtla, Inc. BCAB	$4M	N/A	—	-$50.66
CalciMedica, Inc. CALC	$15M	N/A	—	-$0.00
Celularity Inc. CELU	$19M	N/A	—	-$3.59
Elutia Inc. ELUT	$46M	0.54x	—	$1.29
Lantern Pharma Inc. LTRN	$53M	N/A	—	-$1.57

* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio

About PE Ratio & Methodology

The price-to-earnings (P/E) ratio for RenovoRx, Inc. (RNXT) measures how much investors pay for each dollar of the company's trailing earnings. RNXT's current PE ratio of N/A is calculated by dividing its stock price of $0.90 by its TTM earnings per share of -$0.32.

PE Ratio = Stock Price ÷ EPS (TTM)

= $0.90 ÷ -$0.32 = N/A

TTMTrailing Twelve Months — sum of the most recent 4 quarterly EPS figures

Forward PEStock price ÷ analyst consensus EPS estimate for the next fiscal year

PEGPE ÷ earnings growth rate — values below 1.0 suggest growth may justify the premium

Figures tie to SEC 10-K/10-Q and FMP ratio endpoints where noted.

Price history Financial statements Earnings

Frequently asked questions

RNXT pe ratio · 6 questions

RNXT's current PE ratio is N/A as of 2026-06-09, based on a stock price of $0.90 and TTM EPS of -$0.32. Data sourced from Financial Modeling Prep via RNXT's SEC 10-K and 10-Q filings.

RNXT PE ratioWhat is RNXT PE ratioCurrent PE ratio of RNXTRNXT PE ratio today

▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · RenovoRx, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09